ArticleNanotheranostics2018
A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA).
Article in Nanotheranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.International journal of nanomedicine · 2026Review
- High-Performance Silicon Nanowire Array Biosensor for Combined Detection of Colorectal Cancer Biomarkers.Micromachines · 2025Article
- Recent advances in ctDNA detection using electrochemical biosensor for cancer.Discover oncology · 2024Review
- Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers.ACS biomaterials science & engineering · 2024Review
- Improving electrochemical hybridization assays with restriction enzymes.Chemical communications (Cambridge, England) · 2024Article
- ACEK Biosensor for the Minute-Scale Quantification of Breast Cancer ctDNA.Sensors (Basel, Switzerland) · 2024Article
- Emerging ctDNA detection strategies in clinical cancer theranostics.Smart medicine · 2023Review
- Gold Nanoparticles as a Biosensor for Cancer Biomarker Determination.Molecules (Basel, Switzerland) · 2023Review
- Electrochemical Biosensors for Circulating Tumor DNA Detection.Biosensors · 2022Review
- Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications.Biosensors · 2022Article
- Effects of Tumor-Derived DNA on CXCL12-CXCR4 and CCL21-CCR7 Axes of Hepatocellular Carcinoma Cells and the Regulation of Sinomenine Hydrochloride.Frontiers in oncology · 2022Article
- Rapid and ultrasensitive electrochemical detection of circulating tumor DNA by hybridization on the network of gold-coated magnetic nanoparticles.Chemical science · 2021Article
- Application of electrochemical biosensors in tumor cell detection.Thoracic cancer · 2020Review
- Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Article
- Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.Nanotheranostics · 2020Article
- Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and its Specific Features.Sensors (Basel, Switzerland) · 2019Review
- Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.Cancer management and research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA), which includes DNA mutations, epigenetic alterations and other forms of tumor-specific abnormalities, is a promising "real-time" biomarker for noninvasive cancer assessment. Tumor DNA is of great value in the process of cancer treatment, including diagnostic and prognostic information before, during treatment and at progression. Here we introduce a peptide nucleic acids probe-gold nanoparticles (PNA-AuNPs) and lead phosphate apoferritin (LPA)-based dual biomarker detection platform, which could be used in a DNA biosensor to quantify ctDNA by detection of tumor-specific mutations and methylation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.